Annual report of the Japanese Breast Cancer Registry for 2019.
Minoru MiyashitaHiraku KumamaruNaoki NiikuraYasuaki SagaraTakaaki KonishiTakayuki IwamotoNaoko SanukiKenta TanakuraMasayuki NagahashiNaoki HayashiMasayuki YoshidaChie WatanabeNaoko KinukawaMasakazu ToiShigehira SajiPublished in: Breast cancer (Tokyo, Japan) (2023)
This is an annual report by the Japanese Breast Cancer Society regarding the clinical data on breast cancer extracted from the National Clinical Database-Breast Cancer Registry (NCD-BCR) of Japan. Here, we present an updated summary of 98,300 breast cancer cases registered in 2019. The median age at cancer diagnosis was 61 years (interquartile range 49-72 years), and 30.6% of the breast cancer patients were premenopausal. Of the 93,840 patients without distant metastases, 14,118 (15.0%) and 42,047 (44.8%) were diagnosed with stage 0 and I disease, respectively. Breast-conserving surgery was performed in 42,080 (44.8%) patients. Regarding axillary procedures, 62,677 (66.8%) and 7371 (7.9%) patients underwent sentinel node biopsy and axillary node dissection after biopsy, respectively. Whole breast irradiation was administered to 29,795 (70.8%) of the 42,080 patients undergoing breast-conserving surgery. Chest wall irradiation was administered to 5524 (11.1%) of the 49,637 patients who underwent mastectomy. Of the 6912 clinically lymph node-negative patients who received preoperative therapy, 5250 (76.0%) and 427 (6.2%) underwent sentinel node biopsy and axillary node dissection after biopsy, respectively; however, 602 (8.7%) patients initially underwent axillary node dissection without biopsy.
Keyphrases
- lymph node
- ejection fraction
- newly diagnosed
- patients undergoing
- neoadjuvant chemotherapy
- emergency department
- stem cells
- squamous cell carcinoma
- minimally invasive
- atrial fibrillation
- acute lymphoblastic leukemia
- machine learning
- postmenopausal women
- acute coronary syndrome
- percutaneous coronary intervention
- patient reported outcomes
- deep learning
- cell therapy
- tyrosine kinase
- locally advanced
- patient reported
- artificial intelligence